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Abstract
Background—Current U.S. FDA approved biological therapies for treating smoking target
central nervous system processes. Although these therapies have had some success, relapse within
a year is still high. Clearly additional strategies are needed to aid individuals in maintaining
abstinence.
Objective & Methods—We briefly discuss promising research using vaccines to combat
smoking and then identify some potentially important directions for future research.
Results & Conclusions—Immunization with a nicotine vaccine generates drug-specific
antibodies that sequester some of the nicotine in peripheral circulation preventing it from entering
the brain thus decreasing its addictive effects. Albeit promising, much more research is necessary
to identify more efficacious vaccine designs and formulations, as well as optimal immunization
regimens. A further understanding of the contributing factors to the substantial individual
differences in immunogenicity to these vaccines and how to best use vaccines in combination with
other treatment strategies will increase the success of intervention efforts.
Keywords
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Introduction
Worldwide smoking is the leading cause of preventable deaths and is a substantial personal
burden to individuals (and their loved ones) suffering from smoking-related diseases, as well
as a fiscal burden to society in lost worker productivity and health-care costs [1]. Although a
majority of smokers are motivated to quit, without intervention nearly 95% of those that stop
smoking will relapse within a year [2]. The consensus among the scientific community is
that nicotine is the primary addictive compound in tobacco products. Given the tenacity of
the addiction and the extent of its harm, advances in treatment that increases long-term
cessation rates are needed. To date, all United States FDA approved biological therapies
(varenicline, bupropion, nicotine replacement therapy) target central nervous system (CNS)
processes believed to be involved in nicotine dependence.
In contrast, a recent treatment advance showing promise in preclinical research, as well as in
early treatment trials, uses an immunological approach (i.e., vaccine) to prevent nicotine
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from entering the CNS (e.g.,[3–5]). A vaccinated individual will have antibodies for nicotine
(see Figure 1). If that individual smokes, some portion of the nicotine in periphery (blood
and extracellular fluid) will be sequestered by these antibodies. Because antibodies are too
large to permeate the blood-brain-barrier, less nicotine enters the CNS thus decreasing its
impact on brain systems involved in addiction (e.g., mesocorticolimbic system). For the
generation of an immune response to nicotine, a nicotine vaccine must activate and engage
the necessary cellular components of the innate and acquired arms of the immune system.
Because the nicotine molecule is too small to engage these processes itself, this has been
accomplished to date by an immunoconjugate design in which multiple nicotine haptens are
conjugated (i.e., linked) to a carrier protein. To potentiate the immune response, this
conjugate vaccine is admixed with an adjuvant (e.g., alum) for the final vaccine formulation
[6,7].
Such vaccine designs have clearly demonstrated utility in inducing the anti-nicotine
antibody responses necessary for alteration of nicotine-induced psychoactive effects in
rodents [4,8], and the results from early initial treatment trials with several different vaccine
designs show therapeutic promise [9–11]. Immunotherapies for smoking cessation might
have some advantages over pharmacotherapies [7,12]. A well-designed vaccine will have
good specificity for nicotine over related endogenous ligands (e.g., acetylcholine). This
specificity combined with the fact that vaccines target the nicotine molecule rather than the
CNS processes involved in the addiction translates into fewer side effects [7]. Medications
for smoking cessation (e.g., bupropion, varenicline) require patients to follow daily
instructions for effective treatment. A vaccine approach using active immunization
processes, however, requires an initial vaccination and several follow-up boosts. Fewer side
effects, along with a less effortful treatment protocol (show up for a few appointments) may
enhance patient compliance to treatment [7,12]. A comprehensive review of the research or
immune system processes involving vaccines designed for treating smoking is beyond the
goal and scope of a Future Perspectives article. Thus, we refer the reader to the following
recent reviews [4,6,7] for excellent and detailed discussion of vaccines to combat drug
addiction.
Notable Considerations
The advantages of a vaccine approach just noted prompt discussion of some notable findings
from preclinical and clinical research that require consideration as possible areas for future
research advances into the efficacy of vaccines for treating smoking. For instance, the
immunogenicity of a vaccine formulation varies widely across individuals and, not
surprisingly, the efficacy of any particular vaccine appears directly related to its ability to
raise drug-specific antibodies [9,10]. A better understanding of design and formulation
features of hapten-based vaccines, as well as how these features engage the immune system
and interface with differences between individuals and responsivity to immunization, will
improve future vaccines (cf. [6]). One idea that emerges from this discussion of individual
variability in immunogenicity is the possible use of combinations of different vaccine
designs to increase their overall efficacy. Related to this discussion is the slow onset of
current active immunization protocols, which typically require several temporally spaced
boosters before therapeutically-relevant levels of nicotine-specific antibodies are observed.
Indeed, this lag time from treatment to onset of effectiveness makes active immunization
more likely to be useful for prevention of relapse rather than promoting initial cessation
(7,8). Passive immunization with a monoclonal antibody has been suggested as a solution to
fill this lag; that approach, however, will likely be more expensive and have increased risk
of side effects such as allergic reactions [4,6]. Research advances elucidating the processes
underlying the efficiency and proficiency of each vaccination to induce a drug-specific
immune response, as well as improve the quality of the antibody produced (e.g., increased
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binding affinity, longer half-life, etc.) will enhance the potential utility of vaccines for the
treatment of smoking. Given that nicotine does not appear to have immunogenic effects
alone, continued effectiveness of vaccination treatment requires periodic boosters. Thus,
research should also focus on designs and vaccination regimens that lead to a more
prolonged immune response.
As noted earlier, the efficacy of vaccines against nicotine appears to rely on preventing at
least some portion of nicotine from entering the CNS where it acts on neurobiological
processes underlying drug addiction and dependence. Several individuals have speculated
that antibodies that sequester this portion of nicotine early, before it reaches the CNS, will
be more effective since these early effects appear to mediate reward and other psychoactive
processes maintaining smoking [4–6]. We agree with this conjecture. However, considering
that vaccine effectiveness relies on its ability to function as a pharmacokinetic antagonist
suggests some important questions regarding individual differences. For example, research
with human participants indicates that women are less sensitive to the rewarding effect of
nicotine than men, and that social factors appear particularly important for women [13]. This
finding suggests that nicotine vaccines might be more effective in men than women. More
generally applied, a vaccine might be better suited to individuals for whom the
pharmacological effects of nicotine are critical for maintenance of smoking—regardless of
sex. Alternate interventions may be more effective for those individuals for which cognitive,
behavioral, and social factors are more important. Indeed, the very nature of a vaccine
approach means that it does not directly act on CNS processes mediating implicit or explicit
affective or cognitive processes involved in smoking. As such, a vaccine will likely be most
effective when used in combination with pharmacological and/or cognitive-behavioral
interventions [5,12]. Clearly, research identifying factors that promote smoking for an
individual (age of onset, sensitivity to nicotine, etc.) along with research on effective
combinational treatment approaches that include vaccination will likely improve smoking
cessation efforts.
Expert Opinion
Clearly, much research is still needed to fully appreciate how nicotine vaccines are effective,
as well as what factors will determine effectiveness within and across individuals.
Preclinical and early treatment studies have provided proof-of-principle examining a
relatively small number of variables relevant to the efficacy of vaccines for treating
smoking. We believe that much more programmatic and parametric research is needed on
vaccine design, formulation, and immunization schedule, as well as their impact on nicotine-
specific antibody production and any accompanying changes in the pharmacokinetic and
pharmacodynamic effects of nicotine. This research will likely include how the nicotine
hapten is spaced and/or oriented on the carrier protein, the optimal number of haptens per
carrier protein, how the nicotine is conjugated to the carrier protein, alternates to carrier
protein immunoconjugate designs such as the use of peptide-based molecular adjuvants [14],
and how immunization variables such as number and spacing affect vaccine efficacy [6,7].
The present paper has focused on vaccines against nicotine because the bulk of the research
effort for vaccines to combat smoking has targeted nicotine—the primary addictive
constitute of tobacco. However, other constitutes of tobacco and/or major metabolites of
nicotine (e.g., MAO inhibitors, nornicotine, cotinine, etc.) are thought to contribute to
tobacco addiction (cf. [15,16]). Indeed, a recent paper has provided support for the potential
utility of a vaccine for cotinine, a major metabolite of nicotine [15]. The idea behind a
cotinine vaccine is based on research indicating that this metabolite functions to antagonize
the effects of nicotine in the CNS. By doing so, cotinine decreases the relative efficacy of
nicotine replacement therapy to alleviate withdrawal symptoms—an important factor in
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relapse. Cotinine-specific antibodies from vaccination sequester cotinine in the periphery
prohibiting its entry into the CNS. The net result of this sequestering would be to allow more
nicotine to act in key brain areas involved in withdrawal and supposedly increase the
efficacy of nicotine replacement therapy [15]. This is an interesting proposition that requires
much more research. Further, this proposition suggests that other psychoactive constitutes of
tobacco and/or metabolites of nicotine (e.g., nornicotine) might be therapeutic targets [16].
Writers on the therapeutic uses of vaccines for smoking are virtually unanimous in
considering it as an adjunct with other cognitive-behavioral and/or pharmacological
treatments (e.g.,[4,5,12,15]). This recommendation recognizes that centrally mediated
alterations in affect and cognition resulting from quitting smoking are not targeted by
vaccines. Despite this congruous opinion, there has been little empirical effort to examine
the effectiveness of combination therapies. As clinical trials with vaccines focus more on
smoking cessation and its associated constructs (e.g., withdrawal, cravings, anhedonia) as
outcome variables, we predict that research assessing the vaccine in combination with, say,
bupropion or varenicline will be conducted. Such combinational treatment regimens might
be especially helpful in relapse vulnerable populations that may be more likely to try to
surmount the ability of antibodies to sequester nicotine. Of note, this compensatory smoking
has yet to be reported in early treatment trials. However, these initial studies include
participant exclusion criteria that might not allow sufficient sampling of vulnerable
populations (e.g., alcoholics, schizophrenics, etc.).
Chronic nicotine-dependent smokers seeking help to quit or not to relapse are the primary
target for immunotherapy. However, several authors have noted that vaccines might be used
as a prevention technique in youths that do not smoke or are experimenting [5,6]. If this
suggestion is seriously considered, we hope that extraordinary empirical effort would be
expended not only on “standard” safety, but on more subtle biological effects that could
significantly affect later behavior. For instance, the pharmacokinetic and pharmacodynamic
effects of nicotine in a vaccinated adolescent experimenting with tobacco will differ from a
non-vaccinated individual—antibodies sequestering nicotine slow metabolism, create a
longer elimination half-life, and alter CNS effects. Although these alterations may be
desirable in dependent individuals, the impact of such alterations is unclear in someone that
has had little or no experience with nicotine. In general, retrospective studies suggest that
blunting the early negative (nausea) and/or positive (buzz) effects of the first cigarette might
have protective effects [17,18]. However, these are self-report studies of a past experience.
Furthermore, the long-term neurobiological effects of the altered pharmacodynamics are
unknown. Considering that nicotine acts in brain systems regulating learning, feeding,
anxiety, addiction, etc., it will be very important to ensure that a preventive strategy with a
vaccine does not unintentionally increase vulnerability to other addictions (alcohol,
gambling) or mental health issues.
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Figure 1.
This cartoon diagrams the rationale and mechanism behind a vaccine for the treatment of
nicotine use (e.g., smoking). An individual is vaccinated according to some empirically
determined immunization schedule. Immunization with the nicotine vaccine will activate the
immune system to produce drug-specific antibodies. If an immunized individual then uses a
nicotine-containing product such as cigarettes, some portion of the nicotine in serum and
extracellular fluid will be sequestered by the antibodies. Although nicotine readily passes
through the blood-brain-barrier, antibodies are too large to do so resulting in less nicotine
entering the brain. This decreases nicotine’s impact on brain systems involved in addiction
(e.g., mesocorticolimbic system). Especially effective vaccines will be ones that raise a
robust immune response with the fewest immunization boosts, produce antibodies that are
highly specific for nicotine, and include a binding affinity that allows the initial introduction
of nicotine into the periphery to be sequestered very quickly.
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